Literature DB >> 20008248

Idiopathic erythrocytosis: a disappearing entity.

Mary Frances McMullin1.   

Abstract

Erythrocytosis results when there is an increased red cell mass and thus an increased hemoglobin. The causes can be divided into primary intrinsic defects of the erythroid progenitor cell and secondary defects, where factors external to the erythroid compartment are responsible. Both can then be further divided into congenital and acquired categories. Congenital causes include mutations of the erythropoietin receptor and defects of the oxygen-sensing pathway including VHL, PHD2 and HIF2A mutations. When fully investigated there remain a number of patients in whom no cause can be elucidated who are currently described as having idiopathic erythrocytosis. Investigation should start with a full history and examination. Having eliminated the common entity polycythemia vera, further direction for investigation is guided by the erythropoietin level. Clinical consequences of the various erythrocytoses are not clear, but in some groups thromboembolic events have been described in young patients. Evidence is lacking to define best management, but aspirin and venesection to a target hematocrit should be considered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20008248     DOI: 10.1182/asheducation-2009.1.629

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  17 in total

1.  Clinical utility gene card for: familial erythrocytosis.

Authors:  Kais Hussein; Melanie Percy; Mary Frances McMullin
Journal:  Eur J Hum Genet       Date:  2012-01-25       Impact factor: 4.246

2.  Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis.

Authors:  Ambra Spolverini; Lisa Pieri; Paola Guglielmelli; Alessandro Pancrazzi; Tiziana Fanelli; Chiara Paoli; Alberto Bosi; Ilaria Nichele; Marco Ruggeri; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

3.  The high oxygen affinity haemoglobin Nantes: a family case description.

Authors:  Anna Artuso; Rita Balter; Elisa Bonetti; Chiara Zambon; Anna Ravani; Bernardetta Dolcini; Marina Taddei Masieri; Gian Luca Salvagno; Roberta Zanotti; Giovanni Pizzolo; Dino Veneri
Journal:  Blood Transfus       Date:  2014-12-10       Impact factor: 3.443

4.  Facing erythrocytosis: Results of an international physician survey.

Authors:  Elisa Rumi; Mary F McMullin; Claire Harrison; Martin H Ellis; Merav Barzilai; Nadav Sarid; Ruben Mesa; Chiara Paoli; Anna Angona; Emanuela Sant'Antonio; Virginia V Ferretti; Chiara Cavalloni; Ilaria C Casetti; Chiara Trotti; Tiziano Barbui
Journal:  Am J Hematol       Date:  2019-06-10       Impact factor: 10.047

5.  Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene.

Authors:  Elena Albiero; Marco Ruggeri; Stefania Fortuna; Silvia Finotto; Martina Bernardi; Domenico Madeo; Francesco Rodeghiero
Journal:  Haematologica       Date:  2011-08-09       Impact factor: 9.941

6.  Gene panel sequencing improves the diagnostic work-up of patients with idiopathic erythrocytosis and identifies new mutations.

Authors:  Carme Camps; Nayia Petousi; Celeste Bento; Holger Cario; Richard R Copley; Mary Frances McMullin; Richard van Wijk; Peter J Ratcliffe; Peter A Robbins; Jenny C Taylor
Journal:  Haematologica       Date:  2016-09-20       Impact factor: 9.941

7.  Dissecting Primary Erythrocytosis Among Polycythemia Patients Referred to an Indian Armed Forces Hospital.

Authors:  Harshit Khurana; Praveen Lakshman; Kishore Kumar; Arihant Jain
Journal:  Indian J Hematol Blood Transfus       Date:  2019-07-08       Impact factor: 0.900

8.  Renal transplantation in patients with familial Mediterranean fever.

Authors:  Emre Erdem; Ahmet Karatas; Coskun Kaya; Melda Dilek; Yarkın Kamil Yakupoglu; Nurol Arık; Tekin Akpolat
Journal:  Clin Rheumatol       Date:  2012-05-05       Impact factor: 2.980

Review 9.  Current and future treatment options for polycythemia vera.

Authors:  Martin Griesshammer; Heinz Gisslinger; Ruben Mesa
Journal:  Ann Hematol       Date:  2015-04-02       Impact factor: 3.673

Review 10.  The role of PHD2 mutations in the pathogenesis of erythrocytosis.

Authors:  Betty Gardie; Melanie J Percy; David Hoogewijs; Rasheduzzaman Chowdhury; Celeste Bento; Patrick R Arsenault; Stéphane Richard; Helena Almeida; Joanne Ewing; Frédéric Lambert; Mary Frances McMullin; Christopher J Schofield; Frank S Lee
Journal:  Hypoxia (Auckl)       Date:  2014-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.